Government-Owned Inventions; Availability for Licensing, 32743-32744 [2014-13097]
Download as PDF
<![CDATA[
32743
Federal Register / Vol. 79, No. 109 / Friday, June 6, 2014 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Number of
responses per
respondent
Average burden
per response
(in hours)
Total annual
burden hours
Type of respondent
Data collection type
21
7
1
1
40/60
5/60
14
1
Pilot Project ......................................
Working Group .................................
Coordinating Center .........................
PI/Co-PI ............................................
Telephone Interview ........................
Script to Schedule Telephone Interview.
Telephone Interview ........................
Telephone Interview ........................
Telephone Interview ........................
Expert Panel ....................................
Consent Form ..................................
Telephone Script to Schedule Interview.
Telephone Interview ........................
6
6
2
18
18
6
1
1
1
1
1
1
40/60
40/60
40/60
1.5
5/60
5/60
4
4
1
27
2
1
21
1
40/60
14
..........................................................
........................
........................
Total ..........................................
Dated: June 2, 2014.
Karla Bailey,
NCI Project Clearance Liaison, NCI, NIH.
[FR Doc. 2014–13271 Filed 6–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
wreier-aviles on DSK5TPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
VerDate Mar<15>2010
13:59 Jun 05, 2014
Jkt 232001
RNA Splicing Inhibitors To Treat
Cancers
Description of Technology:
Vemurafenib is a B-Raf enzyme
inhibitor that causes cell death in
melanoma tumor cells that possess a
mutated B-Raf protein (V600E BRAF
mutation); however, patients rapidly
develop resistance. One mechanism for
acquired resistance of these patients to
BRAF inhibitors has been found to be
mediated by the existence of BRAF
(V600E) splicing variants that possess
structural changes in BRAF that confer
insensitivity to BRAF inhibitors.
Researchers at the National Cancer
Institute have discovered that RNA
splicing inhibitors can block the growth
of vemurafenib-resistant tumors.
Further, the researchers have also found
that other types of tumors that possess
BRAF splicing isoforms are susceptible
to RNA splicing inhibitors.
Available for licensing are methods of
using RNA splicing inhibitors to treat
tumors, including melanomas, and
methods to detect tumors that possess
certain BRAF splicing isoforms
susceptible to RNA splicing inhibitors.
Potential Commercial Applications:
Therapeutic agents to treat tumors.
Competitive Advantages: No
discernible toxicity in mice.
Development Stage: Early-stage; In
vitro data available; In vivo data
available (animal).
Inventors: Thomas A. Misteli and
Maayan Salton-Morgenstern (NCI).
Intellectual Property: HHS Reference
No. E–065–2014/0—U.S. Application
No. 61/974,378 filed 02 Apr 2014.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
od.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
..........................
112
commercialize the development of RNA
splicing modulators as therapeutic
agents in cancer. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at hewesj@mail.nih.gov.
Treatment of Chronic Kidney Disease
With Synthetic Amphipathic Peptides
Description of Technology: The
invention is directed to treatment of
chronic kidney disease by administering
a synthetic, amphipathic helical peptide
known as 5A–37pA, and novel
derivatives thereof. Scientists at NIDDK
have demonstrated that invention
peptides antagonize activity of a
particular scavenger receptor known as
CD36. Using an in vivo model, NIDDK
scientists have shown that invention
peptides slowed progression of chronic
kidney disease and can potentially be
utilized as a therapeutic treatment.
Additionally, certain invention
peptides bind selectively to CD36 with
high specificity over other homologous
scavenger receptors. Thus, invention
peptides can be utilized as a research
tool to further evaluate the complex
etiology of chronic kidney disease.
5A–37pA, and derivatives thereof, are
peptide mimetic of apolipoprotein A–1.
These peptides have been described in
NIH owned patents and/or patent
applications (see, for example, U.S.
Patent Nos. 7,572,771 and 8,071,746 and
8,148,323). Use of these peptides, as
well as the novel peptides of this
invention, for the treatment of kidney
diseases is currently available for
licensing.
Potential Commercial Applications:
Therapeutic; Research Tool.
Competitive Advantages: Selective
antagonist of CD36 activity; Specific
binding to CD36 over other scavenger
receptors.
Development Stage: Early-stage; In
vitro data available; In vivo data
available (animal).
E:\FR\FM\06JNN1.SGM
06JNN1
32744
Federal Register / Vol. 79, No. 109 / Friday, June 6, 2014 / Notices
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Inventors: Ana C. Souza (NIDDK),
Peter S. Yuen (NIDDK), Robert A. Star
(NIDDK), Alexander V. Bocharov (CC),
Alan Remaley (NHLBI), Thomas
Eggerman (NIDDK).
Intellectual Property: HHS Reference
No. E–743–2013/0—U.S. Application
No. 61/890,585 filed 14 Oct 2013.
Related Technology: HHS Reference
No. E–114–2004/0.
Licensing Contact: Lauren NguyenAntczak, Ph.D., J.D.; 301–435–4074;
nguyenantczakla@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
Treatment of Chronic Kidney Disease
with 5A–37pA and Derivatives Thereof.
For collaboration opportunities, please
contact Marguerite Miller at
marguerite.miller@nih.gov or 301–496–
9003.
Novel Anti-HIV Proteins From Coral
Reefs
Description of Technology: The
subject invention describes Cnidarins as
a novel class of highly potent proteins
capable of blocking the HIV virus from
penetrating T-cells. Cnidarins were
found in a soft coral collected in waters
off Australia’s northern coast. Cnidarins
can block virus fusion/entry but do not
block viral attachment. In addition,
Cnidarins do not have lectin-like
activity and therefore possibly a unique
mechanism of action. Thus, Cnidarins
may represent important new leads for
HIV microbicides or for systemic
therapeutics for HIV.
Potential Commercial Applications:
Microbicide; Therapeutic; Research tool.
Competitive Advantages: High
potency against HIV; Novel chemical
composition; Family of related proteins;
Unique mechanism of action.
Development Stage: Early-stage; In
vitro data available; Prototype.
Inventors: Barry O’Keefe, James
McMahon, Koreen Ramessar, Chang-yun
Xiong (all of NCI).
Intellectual Property: HHS Reference
No. E–295–2012/0—U.S. Provisional
Patent Application No. 61/925,347 filed
09 Jan 2014.
Licensing Contact: Sally H. Hu, Ph.D.,
M.B.A.; 301–435–5606; hus@
mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize large-scale recombinant
production of cnidarins and evaluation
VerDate Mar<15>2010
13:59 Jun 05, 2014
Jkt 232001
of their broader antiviral activity as well
as additional pre-clinical studies. For
collaboration opportunities, please
contact John D. Hewes, Ph.D. at hewesj@
mail.nih.gov.
Dated: June 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–13097 Filed 6–5–14; 8:45 am]
BILLING CODE 4140–01–P
deainfo.nci.nih.gov/advisory/dclg/dclg.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: June 2, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2014–13098 Filed 6–5–14; 8:45 am]
National Cancer Institute; Notice of
meeting
BILLING CODE 4140–01–P
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Director’s
Consumer Liaison Group.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Cancer
Institute Director’s Consumer Liaison Group.
Date: June 26, 2014.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: NCI Update, Primer on
Immunotherapy, Advocate and
Organizational Engagement Working Group
Discussion.
Place: National Institutes of Health,
Building 31, C-Wing, Rooms 9 & 10, 31
Center Drive, Bethesda, MD 20892
(Teleconference: 1–888–946–9419; Passcode:
9630125)
Contact Person: Amy Bulman, National
Cancer Institute, 31 Center Drive, Building
31, Room 10A28, Bethesda, MD 20892, 301–
496–9723, williaam@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Clinical Trials and
Translational Research Advisory
Committee, July 16, 2014, 09:00 a.m. to
July 16, 2014, 04:00 p.m., National
Institutes of Health, Building 31, 31
Center Drive, Bethesda, MD, 20892
which was published in the Federal
Register on April 18, 2014, 79FR21938.
The meeting is being amended to
change the start and end times from
11:00 a.m. to 1:00 p.m. and the mode of
the meeting is being changed from face
to face to a webinar. Pertinent
information related to the meeting is as
follows:
Date: Wednesday, July 16, 2014.
Time: 11:00 a.m.–1:00 p.m., ET.
Meeting Number: 730 782 390.
Meeting Password: ctac.
Join the online meeting (webinar/
video conference).
Go to: https://cbiit.webex.com/cbiit/
j.php?MTID=m258581e041454e
26f5dbaaa63e54f2. Enter your name and
email address. If required, enter the
meeting password: ctac, then Click
‘‘Join’’. Follow the instructions that
appear on your screen. If/when
prompted to run a temporary
application, click ‘‘Run’’. This may be a
small window that pops up and allows
you to click ‘‘Run’’. It may also be a
small blue link to ‘‘Run a Temporary
Application’’ on the WebEx screen.
Connect to WebEx audio (phone line).
Once you have joined the meeting, an
Audio Conference window will appear
with prompts to enter your number.
E:\FR\FM\06JNN1.SGM
06JNN1
]]>Agencies
[Federal Register Volume 79, Number 109 (Friday, June 6, 2014)]
[Notices]
[Pages 32743-32744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-13097]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology descriptions follow.
RNA Splicing Inhibitors To Treat Cancers
Description of Technology: Vemurafenib is a B-Raf enzyme inhibitor
that causes cell death in melanoma tumor cells that possess a mutated
B-Raf protein (V600E BRAF mutation); however, patients rapidly develop
resistance. One mechanism for acquired resistance of these patients to
BRAF inhibitors has been found to be mediated by the existence of BRAF
(V600E) splicing variants that possess structural changes in BRAF that
confer insensitivity to BRAF inhibitors.
Researchers at the National Cancer Institute have discovered that
RNA splicing inhibitors can block the growth of vemurafenib-resistant
tumors. Further, the researchers have also found that other types of
tumors that possess BRAF splicing isoforms are susceptible to RNA
splicing inhibitors.
Available for licensing are methods of using RNA splicing
inhibitors to treat tumors, including melanomas, and methods to detect
tumors that possess certain BRAF splicing isoforms susceptible to RNA
splicing inhibitors.
Potential Commercial Applications: Therapeutic agents to treat
tumors.
Competitive Advantages: No discernible toxicity in mice.
Development Stage: Early-stage; In vitro data available; In vivo
data available (animal).
Inventors: Thomas A. Misteli and Maayan Salton-Morgenstern (NCI).
Intellectual Property: HHS Reference No. E-065-2014/0--U.S.
Application No. 61/974,378 filed 02 Apr 2014.
Licensing Contact: Patrick McCue, Ph.D.; 301-435-5560;
mccuepat@od.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
the development of RNA splicing modulators as therapeutic agents in
cancer. For collaboration opportunities, please contact John D. Hewes,
Ph.D. at hewesj@mail.nih.gov.
Treatment of Chronic Kidney Disease With Synthetic Amphipathic Peptides
Description of Technology: The invention is directed to treatment
of chronic kidney disease by administering a synthetic, amphipathic
helical peptide known as 5A-37pA, and novel derivatives thereof.
Scientists at NIDDK have demonstrated that invention peptides
antagonize activity of a particular scavenger receptor known as CD36.
Using an in vivo model, NIDDK scientists have shown that invention
peptides slowed progression of chronic kidney disease and can
potentially be utilized as a therapeutic treatment.
Additionally, certain invention peptides bind selectively to CD36
with high specificity over other homologous scavenger receptors. Thus,
invention peptides can be utilized as a research tool to further
evaluate the complex etiology of chronic kidney disease.
5A-37pA, and derivatives thereof, are peptide mimetic of
apolipoprotein A-1. These peptides have been described in NIH owned
patents and/or patent applications (see, for example, U.S. Patent Nos.
7,572,771 and 8,071,746 and 8,148,323). Use of these peptides, as well
as the novel peptides of this invention, for the treatment of kidney
diseases is currently available for licensing.
Potential Commercial Applications: Therapeutic; Research Tool.
Competitive Advantages: Selective antagonist of CD36 activity;
Specific binding to CD36 over other scavenger receptors.
Development Stage: Early-stage; In vitro data available; In vivo
data available (animal).
[[Page 32744]]
Inventors: Ana C. Souza (NIDDK), Peter S. Yuen (NIDDK), Robert A.
Star (NIDDK), Alexander V. Bocharov (CC), Alan Remaley (NHLBI), Thomas
Eggerman (NIDDK).
Intellectual Property: HHS Reference No. E-743-2013/0--U.S.
Application No. 61/890,585 filed 14 Oct 2013.
Related Technology: HHS Reference No. E-114-2004/0.
Licensing Contact: Lauren Nguyen-Antczak, Ph.D., J.D.; 301-435-
4074; nguyenantczakla@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize Treatment of
Chronic Kidney Disease with 5A-37pA and Derivatives Thereof. For
collaboration opportunities, please contact Marguerite Miller at
marguerite.miller@nih.gov or 301-496-9003.
Novel Anti-HIV Proteins From Coral Reefs
Description of Technology: The subject invention describes
Cnidarins as a novel class of highly potent proteins capable of
blocking the HIV virus from penetrating T-cells. Cnidarins were found
in a soft coral collected in waters off Australia's northern coast.
Cnidarins can block virus fusion/entry but do not block viral
attachment. In addition, Cnidarins do not have lectin-like activity and
therefore possibly a unique mechanism of action. Thus, Cnidarins may
represent important new leads for HIV microbicides or for systemic
therapeutics for HIV.
Potential Commercial Applications: Microbicide; Therapeutic;
Research tool.
Competitive Advantages: High potency against HIV; Novel chemical
composition; Family of related proteins; Unique mechanism of action.
Development Stage: Early-stage; In vitro data available; Prototype.
Inventors: Barry O'Keefe, James McMahon, Koreen Ramessar, Chang-yun
Xiong (all of NCI).
Intellectual Property: HHS Reference No. E-295-2012/0--U.S.
Provisional Patent Application No. 61/925,347 filed 09 Jan 2014.
Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301-435-5606;
hus@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate or commercialize
large-scale recombinant production of cnidarins and evaluation of their
broader antiviral activity as well as additional pre-clinical studies.
For collaboration opportunities, please contact John D. Hewes, Ph.D. at
hewesj@mail.nih.gov.
Dated: June 2, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-13097 Filed 6-5-14; 8:45 am]
BILLING CODE 4140-01-P
